Arrowhead Pharmaceuticals, Inc.

Stocks

ARWR

US04280A1007

Market Closed - Nasdaq 16:00:00 2026-10-20 EDT			5-day change	1st Jan Change
58.92 ^USD	+2.95%		+1.36%	-11.25%

09-16	Arrowhead Pharmaceuticals, Inc. Presents at H.C. Wainwright 28th Annual Global Investment Conference, Sep-16-2026 09:00 AM
09-15	Arrowhead Pharmaceuticals, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 11:30 AM

Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call

Published on 08/31/2026 at 09:51 am EDT - Modified on 08/31/2026 at 04:23 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, everyone, and welcome to the Arrowhead Pharmaceuticals Investor Webcast. [Operator Instructions] As a reminder, this call is being

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Arrowhead Pharmaceuticals, Inc.

09-16	Arrowhead Pharmaceuticals, Inc. Presents at H.C. Wainwright 28th Annual Global Investment Conference, Sep-16-2026 09:00 AM
09-15	Arrowhead Pharmaceuticals, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 11:30 AM
09-15	Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for Aro-Dimer-Pa Phase 1/2A Clinical Trial	CI
09-10	Arrowhead Pharmaceuticals, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 10:55 AM
09-08	Citigroup Initiates Arrowhead Pharmaceuticals at Buy With $108 Price Target	MT
08-31	Arrowhead Pharmaceuticals' sHTG Therapy Could Get FDA Approval by Q2 2027, RBC Says	MT
08-31	Arrowhead Pharmaceuticals, Inc. - Special Call
08-31	Arrowhead Pharmaceuticals' Plozasiran Meets Endpoints in Studies of Patients With Severe Hypertriglyceridemia	MT
08-30	Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 And SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events In Patients With Severe Hypertriglyceridemia	CI
08-24	Arrowhead Pharmaceuticals Presents New Clinical Data and Product Updates At European Society of Cardiology Congress	CI
08-20	Arrowhead Pharmaceuticals Insider Sold Shares Worth $1,012,680, According to a Recent SEC Filing	MT
08-17	Arrowhead Pharmaceuticals' Redemplo Now Available in Germany for FCS Patients	MT
08-17	Arrowhead Pharmaceuticals Lists REDEMPLO In Lauer-Taxe Database As Adjunct To Diet To Reduce Triglyceride Levels In Adult Patients With Familial Chylomicronaemia Syndrome In Germany	CI
08-04	Arrowhead Pharmaceuticals, Inc., Q3 2026 Earnings Call, Aug 04, 2026
08-04	Arrowhead Pharmaceuticals Fiscal Q3 Loss Widens, Revenue Rises	MT